Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2010

View Archived Issues

GDNF gene therapy shows promise in Parkinson's disease model

RAD-1901 is efficacious in phase IIa trial in postmenopausal women

Novel RAF kinase inhibitors emerge from Takeda R&D

First-in-human data presented on MLN-9708 in nonhematologic cancer

Serotonin receptor modulators discovered at Nanotherapeutics

Concert Pharmaceuticals claims new deuterated agents

Kagawa Medical University claims new angiogenesis-promoting agents

GSK claims calcium-sensing CaS receptor ligands

Pardoprunox is effective in PD but dose adjustment is needed

Phase III data detailed for add-on safinamide in PD

Versartis commences phase Ia trial of VRS-859 in type 2 diabetes

Reduced melanoma cell growth observed in in vitro testing of GAP-107B8

AstraZeneca and Targacept begin phase III program for TC-5214 in MDD

Phase I trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Infinity enrolling patients in phase I trial of IPI-493 for hematologic malignancies

First patients enrolled in phase I/II study of PVS-10200 for prevention of restenosis

Cellceutix's KM-391shown to increase serotonin levels in preclinical study

Sanofi-aventis begins phase I trial of anticancer agent SAR-650984

Amorfix and QED to co-develop high-affinity monoclonal antibodies for cancer

Anthera begins enrollment in pivotal phase III study of varespladib

EndoTAG-1 effective in triple receptor-negative breast cancer in phase II trial

Merck receives FDA approval for Dulera for asthma in patients 12 years and older

Santaris and miRagen develop microRNA-targeted cardiovascular medicines

FDA advisory committee meeting scheduled to review Contrave NDA

Sanofi-aventis and Metabolex enter into licensing agreement for novel antidiabetic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...